



A monthly report summarizing life science transactions in Washington State.

BY THE NUMBERS: (YTD) **15** TRANSACTIONS **TOTALING OVER** **\$478M**

Deals Per Sector



Disclosed Funding By Sector



JANUARY TOP TRANSACTIONS

Bardy Diagnostics Hillrom, a publicly-traded medical device and digital health company based in Chicago, will pay \$375M to acquire Seattle startup Bardy Diagnostics. Founded in 2013, Bardy set out to change the way medical professionals monitor heart conditions with a non-invasive cardiac monitor patch that helps detect arrhythmia ([GeekWire](#)).

Visus Therapeutics, a clinical-stage pharmaceutical company in pursuit of developing the world's first presbyopia-correcting eye drop with the potential to last a minimum of eight hours, announced the close of a \$36M Series A Preferred Stock financing ([BusinessWire](#)).

Altpep Corporation Seattle-based AltPep Corporation raised \$23.15M in a Series A financing round to take their breakthrough amyloid targeting platform to development ([BioSpace](#)).

OTHER TRENDS & HIGHLIGHTS

Adaptive Biotechnologies announced a translational collaboration with AstraZeneca to investigate the use of immunoSEQ T-MAP, a product that combines the sequencing and mapping capabilities of Adaptive's proprietary immune medicine platform to map T-cell receptors to antigens, across AstraZeneca's oncology portfolio ([Intrado](#)).

Lumen Bioscience received \$33M grant funding from Bill & Melinda Gates Foundation, CARB-X, and U.S. Department of Energy, bringing their total raised to \$54M. Lumen is the developer of a drug development and manufacturing platform intended to transform the way therapeutic drugs are developed ([Pitchbook](#)).

Jubilant HollisterStier Spokane-based Jubilant HollisterStier is planning to double its existing space and manufacturing capacity and add 400 employees during the next three years. The project, which will require an estimated \$70M investment by the company ([Spokane Journal of Business](#)).

TRANSACTIONS

Date	Company	Sector	Type	Amount	Location
01-Jan-2021	Cajal Neuroscience	Biotech	Early Stage VC	undisclosed	Seattle
01-Jan-2021	Healionics	Medtech	Later Stage VC	\$10,760,000	Seattle
01-Jan-2021	Inmedix	Medtech	Seed Round	\$3,580,000	Normandy Park
01-Jan-2021	LumiThera	Medtech	Later Stage VC	undisclosed	Poulsbo
01-Jan-2021	microMend	Medtech	Later Stage VC	undisclosed	Seattle
01-Jan-2021	Nanodropper	Medtech	Accelerator/ Incubator	\$20,000	Seattle
01-Jan-2021	Oisin Biotechnologies	Biotech	Later Stage VC	\$5,090,000	Seattle
01-Jan-2021	OtoNexus Medical Technologies	Medtech	Later Stage VC	\$12,840,000	Seattle
12-Jan-2021	AltPep	Biotech	Early Stage VC	\$23,150,000	Mercer Island
14-Jan-2021	Soovu	Medtech	Later Stage VC	\$1,500,000	Seattle
15-Jan-2021	Bardy Diagnostics	Medtech	Merger/ Acquisition	\$375,000,000	Seattle
15-Jan-2021	Soovu	Medtech	Later Stage VC	\$2,550,000	Seattle
20-Jan-2021	Visus Therapeutics	Biotech	Early Stage VC	\$36,000,000	Seattle
25-Jan-2021	PairTree	Digital Health	Accelerator/ Incubator	\$20,000	Seattle
26-Jan-2021	Parse Biosciences	Biotech	Early Stage VC	\$7,560,000	Seattle
January Total (disclosed transactions): \$478,070,000					